News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 12 - 29

Efung Capital Named to Zero2IPO Annual Ranking: Top 30 Chinese Healthcare Investment Institutions

Today, the 25th China Equity Investment Series Rankings, initiated by the Zero2IPO Research Center under Zero2IPO Holdings, were officially announced. Efung Capital has been named to the Top 30 Chinese Healthcare Investment Institutions list for multiple consecutive years!Since 2001, Zero2IPO Research Center has been publishing annual rankings of China's equity investment industry for 24 consecutive years. Adhering to rigorous scientific research methodologies and a fair, impartial ranking approach, these rankings aim to provide a sound evaluation and benchmarking system for China's eq...

浏览次数：2

查看详情>>

发布时间: 2025 - 12 - 26

National Venture Capital Guidance Fund Officially Launches

On December 26, 2025, the National Venture Capital Guidance Fund was officially launched in Beijing. The three regional funds—the Beijing-Tianjin-Hebei Venture Capital Guidance Fund, the Yangtze River Delta Venture Capital Guidance Fund, and the Greater Bay Area Venture Capital Guidance Fund—formally signed agreements with the first batch of 49 sub-funds and 27 project representatives. This not only marks the implementation of a national-level financial strategic tool but also represents, at the critical juncture where the conclusion of the "14th Five-Year Plan" intersects with the p...

浏览次数：4

查看详情>>

发布时间: 2025 - 12 - 24

Azvudine Combined with PD-1 Efficacy Further Validated! Major Breakthrough in Tumor Immunotherapy

Recently, Genuine Biotech, in collaboration with the First Affiliated Hospital of Zhengzhou University and the Institute of Medicinal Biotechnology at the Chinese Academy of Medical Sciences, published a research paper titled "Azvudine remodels the local immunosuppressive microenvironment and exhibits sustained anti-tumor effects in combination with anti-PD-1 therapies" in Frontiers of Medicine, systematically exploring the anti-tumor efficacy and mechanisms of Azvudine (FNC) combined with anti-PD-1 therapy.The study confirmed that Azvudine monotherapy significantly inhibits sol...

浏览次数：2

查看详情>>

发布时间: 2025 - 12 - 24

First Domestic pVAD Approved by NMPA for Marketing | Fenix Investment Update

Recently, the NMPA announced the approval of Core Medical Technology Co., Ltd.'s percutaneous left ventricular assist device and percutaneous left ventricular assist catheter pump kit for marketing.This system utilizes miniaturized axial motor technology for short-term left ventricular assistance. It represents a domestic首创 technology, filling the technological gap in domestic percutaneous cardiac assist devices.According to research data from several professional institutions, global sales of percutaneous ventricular assist devices (essentially equivalent to pVAD) are expected to reach RM...

浏览次数：1

查看详情>>